AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

Key Points

• AbbVie reaffirmed FY 2026 adjusted EPS guidance of $13.87–$14.07, broadly in line with the $14.02 analyst consensus, and issued third-quarter EPS guidance of $3.84–$3.88. Revenue guidance was not provided in the update.
• Recent results exceeded expectations: second-quarter EPS was $3.65 versus the $3.61 consensus, while revenue rose 10.2% year over year to $16.99 billion. Growth from Skyrizi, Rinvoq and neuroscience products is helping offset continued Humira declines.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $275.95, while AbbVie’s pipeline received a boost from positive etentamig trial results and the $10.9 billion Apogee acquisition; however, the deal is expected to dilute earnings initially.

AbbVie (NYSE:ABBV - Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 13.870-14.070 for the period, compared to the consensus EPS estimate of 14.020. The company issued revenue guidance of -.

Analysts Set New Price Targets

ABBV has been the topic of several research reports. Bank of America raised their target price on AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Cantor Fitzgerald lifted their target price on shares of AbbVie from $265.00 to $285.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. Finally, Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $275.95.

AbbVie Stock Performance

Shares of NYSE ABBV traded down $1.03 during trading on Thursday, hitting $260.69. 2,878,300 shares of the company were exchanged, compared to its average volume of 6,696,391. The company has a fifty day moving average price of $254.23 and a 200-day moving average price of $229.67. The firm has a market capitalization of $460.58 billion, a PE ratio of 73.64, a P/E/G ratio of 1.18 and a beta of 0.29. AbbVie has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 earnings per share. AbbVie's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is presently 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig succeeds in Phase 3 trial: AbbVie said its investigational BCMA x CD3 bispecific T-cell engager met both primary endpoints in the CERVINO study for heavily pretreated relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard available therapies. The monthly dosing schedule and low reported rates of cytokine release syndrome could support outpatient use and help the drug compete in the expanding multiple myeloma market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition completed: AbbVie finalized its approximately $10.9 billion cash acquisition of Apogee Therapeutics NASDAQ: APGE, adding late-stage immunology assets including zumilokibart for atopic dermatitis and APG273 for asthma. The deal broadens AbbVie’s post-Humira growth pipeline and strengthens its dermatology and respiratory franchises. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Core growth remains strong: Analysts highlighted continued momentum from Skyrizi, Rinvoq and neuroscience products, helping offset Humira’s ongoing erosion. AbbVie’s shares are trading above their 50-day and 200-day moving averages, reflecting sustained investor confidence. ABBV Stock Trading Above 50- and 200-Day SMAs
• Neutral Sentiment: AbbVie reaffirmed its 2026 adjusted EPS guidance of $13.87-$14.07 and third-quarter guidance of $3.84-$3.88. Management is scheduled to present at the Morgan Stanley Global Healthcare Conference on September 15.
• Negative Sentiment: The Apogee transaction is expected to dilute earnings in the near term before becoming accretive around 2032. Investors also face continued Humira declines, competitive pressure in oncology and aesthetics, and a crowded multiple myeloma market that could limit etentamig’s eventual commercial opportunity.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the stock. Litman Gregory Wealth Management LLC purchased a new position in AbbVie during the fourth quarter worth about $28,000. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after acquiring an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new stake in shares of AbbVie in the 4th quarter valued at approximately $31,000. Quarry LP acquired a new position in shares of AbbVie in the 3rd quarter worth approximately $41,000. Finally, Jessup Wealth Management Inc acquired a new position in shares of AbbVie in the 4th quarter worth approximately $42,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source